Utilizing MCID for evaluating clinical relevance of AD therapeutic interventions
Abstract With the recent approval of disease‐modifying treatments for mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) by the United States Food and Drug Administration (FDA), Medicines and Healthcare products Regulatory Agency (MHRA), European Medicine Agency's Committee for Medici...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wiley
2025-07-01
|
| Серии: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1002/trc2.70138 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|